申请人:Merck Sharp & Dohme Corp.
公开号:US20160145255A1
公开(公告)日:2016-05-26
Compounds of Formula I:
are HIV reverse transcriptase inhibitors, wherein R
1
, R
2
, R
E
, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
公式I的化合物:是HIV逆转录酶抑制剂,其中R1、R2、RE、L、M和Z在此定义。公式I的化合物及其药学上可接受的盐对于抑制HIV逆转录酶、预防和治疗HIV感染以及预防、延迟发病或进展和治疗AIDS非常有用。这些化合物及其盐可作为药物组成部分,可选地与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。